 CHICAGO and DUBLIN and TREVOSE, Pa., May 24, 2021 PRNewswire -- Xeris Pharmaceuticals, Inc. Nasdaq: XERS, a pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable drug formulations, and Strongbridge Biopharma plc Nasdaq: SBBP, a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that they have entered into a definitive agreement under which Xeris will acquire Strongbridge for stock and contingent value rights CVRs. 